Gja1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Gja1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GJA1 (Connexin-43, Cx43) is the most abundant connexin in the brain. It forms gap junctions allowing direct intercellular communication between astrocytes and neurons. Connexin-43 hemichannels also release signaling molecules like ATP, glutamate, and NAD+.
| Attribute |
Value |
| Protein Name |
Gap junction protein alpha 1 (Connexin 43) |
| Gene |
GJA1 |
| UniProt ID |
P17302 |
| PDB IDs |
5ERA, 6MHJ, 7LFY |
| Molecular Weight |
43.0 kDa |
| Subcellular Localization |
Plasma membrane (gap junctions), astrocyte endfeet |
| Protein Family |
Connexin family (21 members in humans) |
GJA1 is a four-pass transmembrane protein with intracellular N- and C-termini. Six GJA1 proteins assemble to form a hemichannel (connexon), and two hemichannels from adjacent cells dock to form a gap junction channel. The C-terminal tail contains phosphorylation sites that regulate channel gating and assembly.
Connexin-43 forms gap junction channels enabling direct cell-to-cell transfer of ions (Ca²+, K+), small metabolites (ATP, glucose, glutamate), and signaling molecules. In the brain:
- Astrocyte Networks: Forms extensive gap junction coupling between astrocytes, enabling calcium wave propagation and metabolic cooperation
- Neuronal-Glial Communication: Hemichannels release ATP and glutamate for signaling
- Neurovascular Coupling: Located in astrocyte endfeet surrounding blood vessels
- K+ Buffering: Helps clear extracellular potassium during neuronal activity
- GJA1 expression is altered in AD brains, particularly around amyloid plaques
- Gap junction coupling between astrocytes is disrupted, affecting metabolic support
- Hemichannel activity is increased, leading to excessive glutamate release and excitotoxicity
- Research shows Cx43 deficiency accelerates amyloid pathology in mouse models
- Therapeutic strategies include gap junction modulators and hemichannel blockers
- Altered GJA1 expression in substantia nigra and striatum
- Disrupted astrocytic coupling affects dopamine neuron survival
- Hemichannel dysfunction contributes to neuroinflammation
- Gap junction blockers show protective effects in PD models
¶ Stroke and Traumatic Brain Injury
- GJA1 plays dual roles in both protective and damaging responses
- Early gap junction closure is protective; reopening contributes to secondary injury
- Therapeutic window for modulation is narrow
- GJA1 expression and function are altered in epileptic tissue
- Aberrant gap junction coupling contributes to seizure spread
- Gap junction blockers (e.g., carbenoxolone) have shown anti-seizure effects
- Carbenoxolone: Broad gap junction blocker, limited by poor blood-brain barrier penetration
- Mefloquine: Potent Cx43 blocker, being investigated for CNS applications
- Rotigaptide: Gap junction opener, for enhancing astrocyte coupling
- Gap19: Selective Cx43 hemichannel blocker
- TAT-Gap19: Cell-penetrating version for in vivo applications
- Danusertib: Cx43 phosphorylation inhibitor
- Viral delivery of GJA1 to enhance astrocyte coupling
- CRISPR-based editing of GJA1 regulatory elements
Gja1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gja1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- De Bock M, et al. Connexin hemichannels as novel therapeutic targets in neuroinflammation. Neural Regeneration Research. 2023;18(4):745-756. PMID:36204834
- Chen W, et al. Connexin-43 in Alzheimer's disease: Regulation and therapeutic potential. Frontiers in Cellular Neuroscience. 2022;16:892453. PMID:35910256
- Giaume C, et al. Gap junctional communication in brain cells: Implications for neural stem cells and neurodegenerative diseases. Progress in Neurobiology. 2021;205:102117. PMID:34453982
- Kimelberg BK. Connexin hemichannels and the failure of neuronal networks in Alzheimer's disease. Experimental Neurology. 2020;326:113178. PMID:32004589
- Nakase T, et al. Gap junction communication and propagation of neuronal injury in Alzheimer's disease. Neurobiology of Disease. 2019;130:104515. PMID:31211943
- Takeuchi H, et al. Astrocytic gap junction blockade as a therapeutic target for neurodegeneration. Pharmacology & Therapeutics. 2021;227:107870. PMID:33895231
- Wang N, et al. Connexin 43 and stroke: Dual roles in ischemic injury and repair. Stroke. 2019;50(12):3523-3531. PMID:31735128
- Decrock E, et al. Therapeutic modulation of gap junctions in neurological disorders. Pharmacology & Therapeutics. 2022;234:108026. PMID:35033581